This program provides an in‑depth review of the evolving treatment landscape in ovarian cancer with a focus on emerging science and practical application in patient care. Participants will explore the current competitive landscape, new indications, and recent data surrounding folate receptor alpha–targeted therapies. The session will also look ahead to future developments, including the role of antibody–drug conjugates (ADCs) in low‑grade serous ovarian cancer, MEK inhibitors, and the significance of KRAS mutations. Additionally, the course will address the management of adverse events, dose modifications, and strategies to support patients experiencing treatment‑related reactions. A discussion of biomarkers and considerations for first‑line management of recurrent disease will help clinicians make informed, evidence‑based decisions.
What is GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA?
The GOG Foundation, Inc. and GOG Partners are thrilled to share enduring education from Industry Supported Symposia that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year.